Lundbeck profit jumps but warns on generic pressure

Danish pharmaceutical company Lundbeck Wednesday posted a higher than expected quarterly net profit, helped by the expansion of an alliance with Japan's Otsuka and the divestment of a US portfolio of non-core products.

Net profit in the first quarter rose 72 percent to DKK1.07 billion (144 million euros, $189 million) as revenue grew 21 percent to DKK4.58.

Analysts polled by Newswires had expected an average net profit of DKK662.1 million and revenue to come in at DKK4.01 billion.

Chief executive Ulf Wiinberg said he was pleased with the results, but added there was also "reason to be cautious" as Alzheimer's treatment Ebixa would face increased competition from , and launch costs were expected to rise.

"Therefore, we are maintaining the guidance for the year," he said.

The Copenhagen-based company, which has lost in several markets on blockbuster antidepressant Lexapro, said it's "investing significantly in several new product launches and increased pipeline activity."

Lundbeck expects full-year revenue to be between DKK14.4 billion and DKK15.0 billion, and profit from operations (EBIT) to be in the range of DKK1.9 billion to 2.4 billion.

The deal with Otsuka resulted in a DKK284 upfront payment in the period, while Lundbeck gained DKK454 million from the divestment of its US portfolio of non-core products.

add to favorites email to friend print save as pdf

Related Stories

Danish Novo Nordisk profit surges

Jan 31, 2013

Danish pharmaceutical company Novo Nordisk A/S on Thursday reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide begin to approve its ...

Taiwan's HTC expects 30 percent sales plunge in 1Q

Feb 06, 2012

Taiwan's leading smartphone maker HTC forecast Monday that its revenue in the three months to March may plunge 30 percent from a year ago, as competitors Apple and Samsung take their grip on the market.

Diabetes drugs helps boost Novo Nordisk in Q2

Aug 09, 2012

(AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

18 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.